CaMKII inhibition has dual effects on spontaneous Ca 2+ release and Ca 2+ alternans in ventricular cardiomyocytes from mice with a gain-of-function RyR2 mutation

Abstract

Genetically increased RyR2 activity promotes arrhythmogenic Ca 2+ release. Inhibition of CaMKII suppresses RyR2 activity and arrhythmogenic Ca 2+ release. Suppression of RyR2 activity prolongs refractoriness of Ca 2+ release. Prolonged refractoriness of Ca 2+ release leads to arrhythmogenic Ca 2+ alternans. CaMKII inhibition promotes Ca 2+ alternans by prolonging Ca 2+ release refractoriness.

In conditions with abnormally increased activity of the cardiac ryanodine receptor (RyR2), Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) can contribute to a further destabilization of RyR2 that results in triggered arrhythmias. Therefore, inhibition of CaMKII in such conditions has been suggested as a strategy to suppress RyR2 activity and arrhythmias. However, suppression of RyR2 activity can lead to the development of arrhythmogenic Ca 2+ alternans. The aim of this study was to test whether the suppression of RyR2 activity caused by inhibition of CaMKII increases propensity for Ca 2+ alternans. We studied spontaneous Ca 2+ release events and Ca 2+ alternans in isolated left ventricular cardiomyocytes from mice carrying the gain-of-function RyR2 mutation RyR2-R2474S and from wild-type mice. CaMKII inhibition by KN-93 effectively decreased the frequency of spontaneous Ca 2+ release events in RyR2-R2474S cardiomyocytes exposed to the β-adrenoceptor agonist isoprenaline. However, KN-93-treated RyR2-R2474S cardiomyocytes also showed increased propensity for Ca 2+ alternans and increased Ca 2+ alternans ratio compared with both an inactive analog of KN-93 and with vehicle-treated controls. This increased propensity for Ca 2+ alternans was explained by prolongation of Ca 2+ release refractoriness. Importantly, the increased propensity for Ca 2+ alternans in KN-93-treated RyR2-R2474S cardiomyocytes did not surpass that of wild type. In conclusion, inhibition of CaMKII efficiently reduces spontaneous Ca 2+ release but promotes Ca 2+ alternans in RyR2-R2474S cardiomyocytes with a gain-of-function RyR2 mutation. The dominant effect in RyR2-R2474S is to reduce spontaneous Ca 2+ release, which supports this intervention as a therapeutic strategy in this specific condition. However, future studies on CaMKII inhibition in conditions with increased propensity for Ca 2+ alternans should include investigation of both phenomena. NEW & NOTEWORTHY Genetically increased RyR2 activity promotes arrhythmogenic Ca 2+ release. Inhibition of CaMKII suppresses RyR2 activity and arrhythmogenic Ca 2+ release. Suppression of RyR2 activity prolongs refractoriness of Ca 2+ release. Prolonged refractoriness of Ca 2+ release leads to arrhythmogenic Ca 2+ alternans. CaMKII inhibition promotes Ca 2+ alternans by prolonging Ca 2+ release refractoriness.

Genetically increased RyR2 activity promotes arrhythmogenic Ca 2+ release. Inhibition of CaMKII suppresses RyR2 activity and arrhythmogenic Ca 2+ release. Suppression of RyR2 activity prolongs refractoriness of Ca 2+ release. Prolonged refractoriness of Ca 2+ release leads to arrhythmogenic Ca 2+ alternans. CaMKII inhibition promotes Ca 2+ alternans by prolonging Ca 2+ release refractoriness.

In conditions with abnormally increased activity of the cardiac ryanodine receptor (RyR2), Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) can contribute to a further destabilization of RyR2 that results in triggered arrhythmias. Therefore, inhibition of CaMKII in such conditions has been suggested as a strategy to suppress RyR2 activity and arrhythmias. However, suppression of RyR2 activity can lead to the development of arrhythmogenic Ca 2+ alternans. The aim of this study was to test whether the suppression of RyR2 activity caused by inhibition of CaMKII increases propensity for Ca 2+ alternans. We studied spontaneous Ca 2+ release events and Ca 2+ alternans in isolated left ventricular cardiomyocytes from mice carrying the gain-of-function RyR2 mutation RyR2-R2474S and from wild-type mice. CaMKII inhibition by KN-93 effectively decreased the frequency of spontaneous Ca 2+ release events in RyR2-R2474S cardiomyocytes exposed to the β-adrenoceptor agonist isoprenaline. However, KN-93-treated RyR2-R2474S cardiomyocytes also showed increased propensity for Ca 2+ alternans and increased Ca 2+ alternans ratio compared with both an inactive analog of KN-93 and with vehicle-treated controls. This increased propensity for Ca 2+ alternans was explained by prolongation of Ca 2+ release refractoriness. Importantly, the increased propensity for Ca 2+ alternans in KN-93-treated RyR2-R2474S cardiomyocytes did not surpass that of wild type. In conclusion, inhibition of CaMKII efficiently reduces spontaneous Ca 2+ release but promotes Ca 2+ alternans in RyR2-R2474S cardiomyocytes with a gain-of-function RyR2 mutation. The dominant effect in RyR2-R2474S is to reduce spontaneous Ca 2+ release, which supports this intervention as a therapeutic strategy in this specific condition. However, future studies on CaMKII inhibition in conditions with increased propensity for Ca 2+ alternans should include investigation of both phenomena. NEW & NOTEWORTHY Genetically increased RyR2 activity promotes arrhythmogenic Ca 2+ release. Inhibition of CaMKII suppresses RyR2 activity and arrhythmogenic Ca 2+ release. Suppression of RyR2 activity prolongs refractoriness of Ca 2+ release. Prolonged refractoriness of Ca 2+ release leads to arrhythmogenic Ca 2+ alternans. CaMKII inhibition promotes Ca 2+ alternans by prolonging Ca 2+ release refractoriness.